New Delhi: The Serum Institute of India (SII), the world's largest vaccine manufacturer and an effective covid vaccine-like covishield is preparing to launch another corona vaccine in the next few days. The Chief Executive Officer (CEO) of SII, Adar Poonawalla, said on Saturday that the clinical trial of the corona vaccine, Kovax has commenced in India.
He expressed hope that the vaccine could be marketed by September this year. In August, 2020, the US vaccine company Novawax Inc. announced a license agreement with SII. Novawax has made this contract for the development and sale of its corona vaccine 'candidate' NVX-CO2373. The vaccine will be provided to India and lower and middle-income group countries.
In a tweet, Poonawalla wrote, "The trial of Kovax has begun in India. The vaccine is being developed jointly by Novawax and Serum Institute. The vaccine has been tested against the strain of Covid-19 in African and the UK. Its total efficiency has been found to be 89%. We hope that the vaccine can be introduced by September 2021.''